Lemilvo (Aripiprazole)

Aripiprazole modulates brain chemistry by partially stimulating dopamine D2 and serotonin 5‑HT1A receptors while blocking serotonin 5‑HT2A receptors. This balanced activity helps normalize dopamine and serotonin pathways, reducing psychotic symptoms, stabilizing mood, and enhancing antidepressant effects.

The dose of Lemilvo is individualized by the prescribing clinician based on the specific indication, severity of symptoms, patient age, renal and hepatic function, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for aripiprazole in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lemilvo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many atypical antipsychotics, aripiprazole has a unique partial‑agonist profile that may result in a lower incidence of certain side effects such as prolactin elevation and metabolic disturbances. However, individual response varies, and clinicians consider efficacy, tolerability, drug‑drug interactions and patient history when selecting therapy.

Lemilvo tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label.

Lemilvo is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients must follow the dosing schedule prescribed by their clinician and should not crush or split the tablet unless instructed.

Serious risks include the development of tardive dyskinesia, neuroleptic malignant syndrome, and the emergence or worsening of suicidal thoughts, especially in patients with depressive disorders. Any sudden changes in mood, muscle rigidity, high fever, or involuntary movements should prompt immediate medical attention.

Lemilvo is contraindicated in individuals with known hypersensitivity to aripiprazole or any of its excipients. It should be used with caution in patients with severe cardiovascular disease, uncontrolled diabetes, or a history of seizures, and it is generally avoided in patients with dementia‑related psychosis due to increased mortality risk.